JP5543966B2 - Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 - Google Patents

Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 Download PDF

Info

Publication number
JP5543966B2
JP5543966B2 JP2011517911A JP2011517911A JP5543966B2 JP 5543966 B2 JP5543966 B2 JP 5543966B2 JP 2011517911 A JP2011517911 A JP 2011517911A JP 2011517911 A JP2011517911 A JP 2011517911A JP 5543966 B2 JP5543966 B2 JP 5543966B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
pain
sulfonyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011517911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528020A (ja
JP2011528020A5 (enExample
Inventor
ジョフン ベスウイクク パウル
クアムプベルル アルイステル
ペテル クリドルアンド アンドレウ
ジャメス グルエアブエ ロベルト
パウル ヘエル ジャグ
フベルト ニクホルソン ネブイルルエ
ウイルルイアム パゲ ルエエ
ブイルエ サドイエ
Original Assignee
クオンベルゲンセ プハルマセウトイカルス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クオンベルゲンセ プハルマセウトイカルス リミテッド filed Critical クオンベルゲンセ プハルマセウトイカルス リミテッド
Publication of JP2011528020A publication Critical patent/JP2011528020A/ja
Publication of JP2011528020A5 publication Critical patent/JP2011528020A5/ja
Application granted granted Critical
Publication of JP5543966B2 publication Critical patent/JP5543966B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011517911A 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体 Expired - Fee Related JP5543966B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0813142.7 2008-07-17
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds
PCT/EP2009/059012 WO2010007073A1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators

Publications (3)

Publication Number Publication Date
JP2011528020A JP2011528020A (ja) 2011-11-10
JP2011528020A5 JP2011528020A5 (enExample) 2012-08-30
JP5543966B2 true JP5543966B2 (ja) 2014-07-09

Family

ID=39737239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011517911A Expired - Fee Related JP5543966B2 (ja) 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体
JP2011517910A Expired - Fee Related JP5688850B2 (ja) 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011517910A Expired - Fee Related JP5688850B2 (ja) 2008-07-17 2009-07-15 Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体

Country Status (19)

Country Link
US (3) US8530478B2 (enExample)
EP (2) EP2300432B1 (enExample)
JP (2) JP5543966B2 (enExample)
KR (1) KR101599087B1 (enExample)
CN (1) CN102099337B (enExample)
AR (1) AR072809A1 (enExample)
AU (1) AU2009272762B2 (enExample)
BR (1) BRPI0916622A2 (enExample)
CA (1) CA2730471C (enExample)
EA (1) EA018621B1 (enExample)
ES (2) ES2396960T3 (enExample)
GB (1) GB0813142D0 (enExample)
IL (1) IL210446A (enExample)
MX (1) MX2011000600A (enExample)
PL (1) PL2300432T3 (enExample)
TW (1) TW201016677A (enExample)
UY (1) UY31990A (enExample)
WO (2) WO2010007073A1 (enExample)
ZA (1) ZA201100014B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB201000685D0 (en) * 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
US8933132B2 (en) * 2011-01-19 2015-01-13 Convergence Pharmaceuticals Limited Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
EA032638B1 (ru) * 2014-04-14 2019-06-28 Грюненталь Гмбх Арилзамещенные гетероциклилсульфоны
US9879000B2 (en) * 2014-04-14 2018-01-30 Grünenthal GmbH Heteroaryl substituted heterocyclyl sulfones
GB201516183D0 (en) * 2015-09-14 2015-10-28 Calchan Ltd Novel pharmaceutical composition
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
EP3615521A4 (en) * 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
CN118085389B (zh) * 2024-03-11 2024-11-05 伟建实业(苏州)有限公司 一种环保型抗菌海绵及其制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006371A1 (fr) 1987-02-13 1988-08-25 Mitsubishi Denki Kabushiki Kaisha Demarreur/chargeur pour moteurs
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5498711A (en) 1993-02-03 1996-03-12 Thiokol Corporation Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
EP0820452B1 (en) 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
FR2744450A1 (fr) 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
GB9623283D0 (en) 1996-11-08 1997-01-08 Zeneca Ltd Heterocyclic derivatives
US6359134B1 (en) 1997-05-30 2002-03-19 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2001076693A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2812198B1 (fr) 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
JP4365102B2 (ja) 2001-04-26 2009-11-18 コーロン ライフ サイエンス インク 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物
DE10155684A1 (de) 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
RU2323935C2 (ru) 2002-04-18 2008-05-10 Шеринг Корпорейшн Производные бензимидазола, их применение и фармацевтическая композиция на их основе, обладающая свойствами антагониста рецептора гистамина h3
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
DE10319435B4 (de) * 2003-04-25 2018-07-26 Whitecryption Corporation Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2559285A1 (en) 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
DE102004035672A1 (de) 2004-07-22 2006-03-30 Windmöller & Hölscher Kg Verkürzte Stapelbildung
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
DE102004054053A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
EP1965799A2 (en) 2005-12-22 2008-09-10 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
NZ578063A (en) 2006-12-18 2011-09-30 7Tm Pharma As Cannabinoid CB1 receptor modulators
US7648979B2 (en) 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JP5380435B2 (ja) 2007-05-31 2014-01-08 ユーロ−セルティーク ソシエテ アノニム アミド化合物およびその使用
EP2164325B1 (en) 2007-05-31 2013-04-24 Shionogi&Co., Ltd. Oxyimino compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ES2428326T3 (es) 2007-10-04 2013-11-07 Merck Sharp & Dohme Corp. Derivados de aril sulfona sustituida como bloqueadores de canales de calcio
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP2300432B1 (en) 2012-10-03
BRPI0916622A2 (pt) 2019-04-09
MX2011000600A (es) 2011-05-24
EP2346828B1 (en) 2012-10-03
GB0813142D0 (en) 2008-08-27
WO2010007073A1 (en) 2010-01-21
EP2346828A1 (en) 2011-07-27
ES2396960T3 (es) 2013-03-01
US20110130379A1 (en) 2011-06-02
ZA201100014B (en) 2011-09-28
AU2009272762A1 (en) 2010-01-21
ES2396962T3 (es) 2013-03-01
CA2730471A1 (en) 2010-01-21
EP2300432A1 (en) 2011-03-30
TW201016677A (en) 2010-05-01
PL2300432T3 (pl) 2013-03-29
US20120302746A1 (en) 2012-11-29
IL210446A (en) 2014-01-30
WO2010007072A1 (en) 2010-01-21
JP2011528020A (ja) 2011-11-10
CA2730471C (en) 2016-12-06
KR20110031199A (ko) 2011-03-24
JP5688850B2 (ja) 2015-03-25
US8288388B2 (en) 2012-10-16
CN102099337B (zh) 2013-08-21
AU2009272762B2 (en) 2013-08-15
US8530478B2 (en) 2013-09-10
KR101599087B1 (ko) 2016-03-02
CN102099337A (zh) 2011-06-15
US20100022555A1 (en) 2010-01-28
UY31990A (es) 2010-01-05
AR072809A1 (es) 2010-09-22
EA201170209A1 (ru) 2011-08-30
JP2011528019A (ja) 2011-11-10
EA018621B1 (ru) 2013-09-30
IL210446A0 (en) 2011-03-31
US8536183B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
JP2011528020A (ja) Cav2.2カルシウムチャネルモジュレーターとして使用されるピペラジン誘導体
CN111601807B (zh) Menin-mll相互作用的外型-氮杂螺抑制剂
CN108026105B (zh) TGFβ受体拮抗剂
AU2017232906A1 (en) Small molecules against cereblon to enhance effector T cell function
CN115698001A (zh) 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
WO2010102663A1 (en) Piperazine derivatives for use in therapy
JP5611201B2 (ja) ピラゾロ[1,5−a]ピリミジン誘導体
WO2023125376A1 (zh) 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
AU2013242858B2 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
JP5785953B2 (ja) CaV2.2カルシウムチャンネルを遮断するためのピペラジン誘導体
WO2024175026A1 (zh) 含氮杂环类化合物及其医药用途
HK40111960A (en) Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
CN118812520A (zh) 一种苯并咪唑-6-羧酸类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140509

R150 Certificate of patent or registration of utility model

Ref document number: 5543966

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees